Tonix Pharmaceuticals Holding Corp. 8-K

What Happened

• Tonix Pharmaceuticals (TNXP) announced on May 27, 2026 that a peer‑reviewed manuscript was published in the Journal of Clinical Immunology reporting first‑in‑human Phase 1 results for TNX‑1500, an Fc‑modified anti‑CD154 monoclonal antibody. The filing (Form 8‑K) attaches a press release (Exhibit 99.01) and the manuscript (Exhibit 99.02).
• The study was a single‑center, randomized, double‑blind, placebo‑controlled, single‑ascending dose escalation trial in 26 healthy adults. Participants received a single IV infusion of TNX‑1500 (3, 10 or 30 mg/kg) or placebo, followed by KLH immunizations on days 2 and 29 and 120 days of follow‑up.
• Pharmacodynamic results: TNX‑1500 blocked the primary T cell‑dependent antibody response (TDAR) to KLH at all doses, blocked the secondary TDAR at 10 and 30 mg/kg, and reduced peak secondary response by ~70% versus placebo at the 3 mg/kg dose.

Key Details

• Study size: 26 healthy adult volunteers.
• Dose cohorts: single IV doses of 3, 10 and 30 mg/kg (or placebo).
• Outcome: primary TDAR blocked at all doses; secondary TDAR blocked at 10 and 30 mg/kg; ~70% reduction in peak secondary response at 3 mg/kg vs placebo.
• Publication date: Manuscript published / press release issued May 27, 2026 in the Journal of Clinical Immunology.

Why It Matters

• These Phase 1 data show target engagement and meaningful immune suppression (TDAR) after single doses in healthy volunteers, which supports TNX‑1500’s mechanism as an anti‑CD154 agent for transplant rejection prevention and autoimmune indications.
• For investors, the results are an early clinical milestone that may de‑risk the program’s biological effect, but this is not patient efficacy data and further trials in patients and longer safety data are required.
• The company included standard forward‑looking statement cautions in the filing; outcomes and timelines remain subject to clinical, regulatory and other risks.